We are delighted to report that recent experiments have enabled us to identify biomarkers for lung, pancreatic, stomach and colon cancers. This means that, whereas to this point most of our work was focused on the early detection of a single-cancer type, we are able to expand our work into an even more exciting direction.
Dr Sophia Fang, our Chief Scientific Officer, said: “Over the past three weeks we have identified a pan-cancer biomarker panel that has been proven effective for multiple cancers using a simple PCR assay. Preliminary clinical validation data supports its efficacy. We are optimistic that this panel will be applicable to additional tumor types, and we are expanding the sample size for further clinical validation.”
Real scientific breakthroughs do not happen every day. But the experiments conducted in our Brooklyn laboratory have enabled such a breakthrough and, as Epi One CEO Michael Marquardt states with our StartEngine crowdfunding campaign in mind: “This will add significant value to our company.”
The equity crowdfunding campaign is now live on StartEngine, offering investors the chance to be a part of Epi One’s growth and innovation. You can find details of the offering at StartEngine’s Epi One offering page.
